FogPharma has announced a $178 Million Series D financing to support development of a proprietary class of precision medicines—Helicon polypeptide therapeutics—that could address a wide range of targets, including some previously considered “undruggable.” FOG-001, a first-in-class direct TCF-blocking β-catenin inhibitor, is expected to enter clinical development for colorectal cancer in…

New research from the University of Texas MD Anderson Cancer Center says that colorectal cancer patients with certain clinical characteristics may benefit from more frequent screening via chest imaging to help identify and target cancer that has metastasized to the lungs. While survival rates are improving due to improved screening…

Researchers from the Perlmutter Cancer Center at NYU Langone Health have detailed a new approach to cancer treatment that seeks to overcome tumors’ evasion of immune surveillance. The investigators show that drugs form stable attachments with the disease-related proteins they target inside cancer cells. The researchers used prior knowledge that…

Researchers at Scripps Research Institute have have uncovered what may be behind the role played by circadian rhythm disruption and increased lung cancer tumor burden. The details of the findings or their mouse study were published recently in Science Advances. “Disrupted circadian rhythmicity is a prominent feature of modern society…

QIAGEN and Neuron23 have announced a collaboration to develop a companion diagnostic for the biotech’s LRRK2 inhibitor, which is currently in the late stages of preclinical development for Parkinson’s disease. This will be the first such test for Parkinson’s if both products are approved. Neuron23 is an early stage biotechnology…

According to the CDC, the general five-year survival rate for people with pancreatic cancer in the United States is 11%. Better treatments and understanding of the disease are needed. A new study in mice, published in Nature Genetics, by researchers at Washington University School of Medicine in St. Louis reveals…

The protein GREM1 Is a key regulator of cellular heterogeneity in mouse and human pancreatic cancer, according to recent work from The Institute of Cancer Research (ICR), London. According to this work manipulating GREM1 levels can fuel or reverse the ability of pancreatic cancer cells to change into a more…

The LUNGevity Foundation announced this week it has launched the Rare Mutations and Fusions Lung Cancer Patient Gateway that will provide patients with non-small cell lung cancer (NSCLC)—and their caregivers—with information on best treatment options, as well as access to educational webinars and support from the community of gateway users.…

A new form of macular dystrophy, an eye disease that affects a small part of the light-sensing retina needed for sharp, central vision, has been discovered by a team of researchers for the National Eye Institute (NEI), a part of the National Institutes for Health (NIH). The findings were reported…

The fight against cancer is often lost once tumor cells become resistant to treatment, more aggressive, and spread throughout the body. Now researchers are revealing the secrets behind tumor evolution, shedding light on the mechanisms that eventually create the most deadly of cancers. At the center of this new effort…

A sequential drug treatment approach that can reverse the resistance of leukemia cells to tyrosine kinase inhibitor (TKI) treatment has been developed by scientists at Barts Cancer Institute at Queen Mary University of London. By rewiring the inner workings of the cancer cells and inhibiting a certain enzyme, the team…

Leukemia Non-Responders to CAR-T Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results from researchers at the National Cancer Institute (NCI) “We identified a signature of nonresponse that is…

Scientists from the University of California (UC), San Diego, and their collaborators have demonstrated how key proteins act together to suppress antitumor activity in high-grade serous ovarian carcinoma (HGSOC) in a mouse model, revealing a new combinatorial strategy to treat this intractable malignancy. Hallmarks of a lethal form of ovarian…

The terms minimal residual disease, measurable residual disease, and molecular residual disease, interchangeably referred to as MRD, denote what is left after cancer treatment with curative intent. Originally used to monitor patients with hematologic malignancies, MRD is becoming increasingly important in the field of solid tumor oncology because of its…

The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, in association with HonorHealth Research and Innovation Institute and Systems Biology Ireland (SBI), have begun a clinical trial, testing the combination of two drugs against advanced pancreatic cancer, one of the most deadly and difficult-to-treat malignancies. The trial combines two drugs — Vemurafenib…